New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time
By HospiMedica International staff writers Posted on 03 Aug 2020 |
Image: New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time (Photo courtesy of FSVO/Renate Boss)
A Swiss-German team of researchers have developed a test that determines the amount of neutralizing antibodies against SARS-CoV-2 within a short period of time.
The test was developed at the Institute of Virology and Immunology (IVI) of the University of Bern (Bern, Switzerland) and the Swiss Federal Office for Food Safety and Animal Health (Köniz, Switzerland), and evaluated by the Ruhr-University Bochum (RUB Bochum, Germany) using serum samples from COVID-19 patients.
To determine immunity to SARS-CoV-2 and the effectiveness of potential vaccines, the amount of neutralizing antibodies in the blood of recovered or vaccinated individuals must be determined. A traditional neutralization test usually takes two to three days and must be carried out with infectious coronaviruses in a laboratory complying with biosafety level 3. The new test launched by the team of Swiss-German researchers takes only 18 hours and does not have high biosafety requirements.
In order to detect antibodies against SARS-CoV-2, the researchers used another virus that does not propagate and exchanged the envelope protein of this virus for the spike protein of the novel coronavirus, which mediates virus entry and infection. As a result, the viruses can be identified by antibodies against SARS-CoV-2 that bind to the viruses which have been altered in this way and neutralize them so that they can no longer penetrate the host cells. Since the virus pseudotyped in this way cannot propagate in host cells, no elaborate biosafety precautions are necessary for the test.
In order to determine the amount of antibodies, the researchers genetically modified the virus so that green fluorescent protein and luciferase, an enzyme from fireflies, will be produced by the infected cells. The green fluorescence is an indicator of infection with the pseudotyped virus. The less green cells found, the more neutralizing antibodies are present which block the virus. In addition, a luminometer can be used to read the luminescence signal produced by the luciferase enzyme – another way of evaluating the test.
In order to check the reliability and comparability with the conventional neutralization test, the researchers applied it to blood samples from COVID-19 patients. The direct comparison showed a good correlation between the two test systems. As compared to 56 hours for the conventional test, the new test is much faster, with only 18 hours to test results.
Related Links:
University of Bern
Swiss Federal Office for Food Safety and Animal Health
Ruhr-University Bochum
The test was developed at the Institute of Virology and Immunology (IVI) of the University of Bern (Bern, Switzerland) and the Swiss Federal Office for Food Safety and Animal Health (Köniz, Switzerland), and evaluated by the Ruhr-University Bochum (RUB Bochum, Germany) using serum samples from COVID-19 patients.
To determine immunity to SARS-CoV-2 and the effectiveness of potential vaccines, the amount of neutralizing antibodies in the blood of recovered or vaccinated individuals must be determined. A traditional neutralization test usually takes two to three days and must be carried out with infectious coronaviruses in a laboratory complying with biosafety level 3. The new test launched by the team of Swiss-German researchers takes only 18 hours and does not have high biosafety requirements.
In order to detect antibodies against SARS-CoV-2, the researchers used another virus that does not propagate and exchanged the envelope protein of this virus for the spike protein of the novel coronavirus, which mediates virus entry and infection. As a result, the viruses can be identified by antibodies against SARS-CoV-2 that bind to the viruses which have been altered in this way and neutralize them so that they can no longer penetrate the host cells. Since the virus pseudotyped in this way cannot propagate in host cells, no elaborate biosafety precautions are necessary for the test.
In order to determine the amount of antibodies, the researchers genetically modified the virus so that green fluorescent protein and luciferase, an enzyme from fireflies, will be produced by the infected cells. The green fluorescence is an indicator of infection with the pseudotyped virus. The less green cells found, the more neutralizing antibodies are present which block the virus. In addition, a luminometer can be used to read the luminescence signal produced by the luciferase enzyme – another way of evaluating the test.
In order to check the reliability and comparability with the conventional neutralization test, the researchers applied it to blood samples from COVID-19 patients. The direct comparison showed a good correlation between the two test systems. As compared to 56 hours for the conventional test, the new test is much faster, with only 18 hours to test results.
Related Links:
University of Bern
Swiss Federal Office for Food Safety and Animal Health
Ruhr-University Bochum
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans